Aliases & Classifications for Dementia

MalaCards integrated aliases for Dementia:

Name: Dementia 12 76 54 29 55 6 43 3 44 15 40 73
Presenile Dementia 73

Classifications:



External Ids:

Disease Ontology 12 DOID:1307
ICD9CM 35 290.8
MeSH 44 D003704

Summaries for Dementia

NINDS : 54 Dementia is the loss of cognitive functioning—the ability to think, remember, problem solve or reason—to such an extent that it interferes with a person’s daily life and activities. Dementia ranges in severity from the mildest stage, when it is just beginning to affect a person’s functioning, to the most severe stage, when the person must depend completely on others for basic activities of daily living. Functions affected include memory, language skills, visual perception, problem solving, self-management, and the ability to focus and pay attention. Some people with dementia cannot control their emotions, and their personalities may change. Signs and symptoms of dementia result when once-healthy neurons (nerve cells) in the brain stop working, lose connections with other brain cells, and die. While everyone loses some neurons as they age, people with dementia experience far greater loss. Unlike dementia, age-related memory loss isn’t disabling. While dementia is more common with advanced age (as many as half of all people age 85 or older may have some form of dementia), it is not normal part of aging. Many people live into their 90s and beyond without any signs of dementia. The causes of dementia can vary. Many people with dementia have both Alzheimer’s disease and one or more closely related disorders that share brain scanning or clinical (and sometimes both) features with Alzheimer’s disease. When a person is affected by more than one dementia disorder, the dementia can be referred to as a mixed dementia. Some people may have mixed dementia caused by Alzheimer’s-related neurodegenerative processes, vascular disease-related processes, or another neurodegenerative condition. Many other conditions such as Creutzfeldt-Jakob disease, Huntington’s Disease, and chronic traumatic encephalopathy can cause dementia or dementia-like symptoms. Risk factors for dementia include advancing age, stroke, high blood pressure, poorly controlled diabetes, and a thickening of blood vessel walls (atherosclerosis). Other dementias include frontotemporal disorders, vascular dementia, and Lewy body dementia.

MalaCards based summary : Dementia, also known as presenile dementia, is related to vascular dementia and dementia, lewy body, and has symptoms including seizures, tremor and angina pectoris. An important gene associated with Dementia is MAPT (Microtubule Associated Protein Tau), and among its related pathways/superpathways are Neuroscience and p75(NTR)-mediated signaling. The drugs Dopamine and Memantine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and heart, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A cognitive disorder resulting from a loss of brain function affecting memory, thinking, language, judgement and behavior.

MedlinePlus : 43 Dementia is the name for a group of symptoms caused by disorders that affect the brain. It is not a specific disease. People with dementia may not be able to think well enough to do normal activities, such as getting dressed or eating. They may lose their ability to solve problems or control their emotions. Their personalities may change. They may become agitated or see things that are not there. Memory loss is a common symptom of dementia. However, memory loss by itself does not mean you have dementia. People with dementia have serious problems with two or more brain functions, such as memory and language. Although dementia is common in very elderly people, it is not part of normal aging. Many different diseases can cause dementia, including Alzheimer's disease and stroke. Drugs are available to treat some of these diseases. While these drugs cannot cure dementia or repair brain damage, they may improve symptoms or slow down the disease. NIH: National Institute of Neurological Disorders and Stroke

CDC : 3 Although scientists are learning more every day, right now, they still do not know what causes Alzheimer’s disease.

Wikipedia : 76 Dementia is a broad category of brain diseases that cause a long-term and often gradual decrease in the... more...

Related Diseases for Dementia

Diseases related to Dementia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 740)
# Related Disease Score Top Affiliating Genes
1 vascular dementia 34.4 APOE APP MAPT PSEN1
2 dementia, lewy body 34.1 APOE APP GBA GRN MAPT PRNP
3 semantic dementia 34.1 APOE C9orf72 CHMP2B GRN MAPT PSEN1
4 frontotemporal dementia 34.0 APOE APP C9orf72 CHCHD10 CHMP2B FUS
5 frontotemporal dementia and/or amyotrophic lateral sclerosis 1 34.0 C9orf72 CHCHD10 CHMP2B FUS GRN MAPT
6 inclusion body myopathy with paget disease of bone and frontotemporal dementia 33.9 TARDBP VCP
7 frontotemporal lobar degeneration with tdp43 inclusions, grn-related 33.7 GRN MAPT
8 alzheimer disease 33.7 APOE APP GRN ITM2B MAPT PRNP
9 binswanger's disease 33.5 APOE APP MAPT
10 behavioral variant of frontotemporal dementia 33.4 C9orf72 CHMP2B GRN MAPT PSEN1 SQSTM1
11 pick disease of brain 33.4 APOE APP FUS GRN MAPT PSEN1
12 creutzfeldt-jakob disease 33.1 APOE MAPT PRNP
13 amyotrophic lateral sclerosis 1 33.0 APP C9orf72 CHCHD10 CHMP2B FUS GRN
14 prion disease 33.0 APP MAPT PRNP
15 leukoencephalopathy, hereditary diffuse, with spheroids 32.9 APP MAPT PRNP SNCA
16 kohlschutter-tonz syndrome 32.9 APOE APP MAPT PSEN1 TYROBP
17 supranuclear palsy, progressive, 1 32.4 APOE APP C9orf72 GRN MAPT PSEN1
18 parkinson disease, late-onset 32.3 APOE APP GBA MAPT SNCA SNCB
19 cerebral amyloid angiopathy, cst3-related 32.3 APOE APP ITM2B MAPT PRNP PSEN1
20 aphasia 32.2 APOE APP C9orf72 CHMP2B GRN MAPT
21 corticobasal degeneration 32.2 GBA MAPT TARDBP
22 posterior cortical atrophy 32.2 APOE MAPT
23 multiple system atrophy 1 32.2 MAPT SNCA SNCB SQSTM1
24 alzheimer disease 2 32.1 APOE APP MAPT PSEN1
25 progressive non-fluent aphasia 32.1 C9orf72 CHMP2B GRN MAPT PSEN1 VCP
26 amyotrophic lateral sclerosis type 14 32.0 FUS TARDBP UBQLN2 VCP
27 synucleinopathy 32.0 APP CHMP2B GBA MAPT SNCA SNCB
28 amyotrophic lateral sclerosis 21 31.8 C9orf72 FUS TARDBP VCP
29 perry syndrome 31.8 C9orf72 GRN SNCA TARDBP
30 amyotrophic lateral sclerosis type 6 31.7 FUS TARDBP
31 kluver-bucy syndrome 31.6 APP MAPT PSEN1
32 familial idiopathic basal ganglia calcification 31.6 APOE APP MAPT PSEN1
33 alzheimer disease 4 31.5 APOE PSEN1
34 lateral sclerosis 31.4 C9orf72 CHCHD10 FUS SQSTM1 TARDBP TRPM7
35 motor neuron disease 31.0 C9orf72 CHCHD10 FUS GRN MAPT SNCA
36 apraxia 30.9 C9orf72 GRN MAPT PSEN1
37 tremor 30.7 FUS GBA MAPT SNCA
38 cerebrovascular disease 30.7 APOE APP MAPT
39 movement disease 30.6 GBA MAPT SNCA
40 amyloidosis 30.5 APOE APP PSEN1 SNCA
41 agraphia 30.5 GRN MAPT PRNP PSEN1 TARDBP
42 alexia 30.5 APOE PSEN1 TARDBP
43 prosopagnosia 30.2 GRN PSEN1
44 postencephalitic parkinson disease 30.2 MAPT SNCA TARDBP
45 early-onset, autosomal dominant alzheimer disease 30.1 APP PSEN1
46 gait apraxia 30.0 APOE APP GRN PSEN1
47 nominal aphasia 30.0 CHMP2B GRN MAPT PSEN1 TARDBP
48 disease of mental health 29.9 APOE APP C9orf72 GRN MAPT PSEN1
49 simultanagnosia 29.8 APOE MAPT
50 senile plaque formation 29.8 APOE APP

Graphical network of the top 20 diseases related to Dementia:



Diseases related to Dementia

Symptoms & Phenotypes for Dementia

UMLS symptoms related to Dementia:


seizures, tremor, angina pectoris, back pain, pain, headache, syncope, chronic pain, sciatica, vertigo/dizziness, equilibration disorder, sleeplessness

GenomeRNAi Phenotypes related to Dementia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 10.12 TRPM7 TYROBP
2 Decreased viability GR00221-A-2 10.12 TRPM7
3 Decreased viability GR00221-A-4 10.12 FUS TRPM7
4 Decreased viability GR00231-A 10.12 SQSTM1
5 Decreased viability GR00342-S-2 10.12 TRPM7
6 Decreased viability GR00381-A-1 10.12 SQSTM1 VCP
7 Decreased viability GR00402-S-2 10.12 APOE APP C9orf72 CHCHD10 CHMP2B FUS
8 no effect GR00402-S-1 9.62 APOE APP C9orf72 CHCHD10 CHMP2B FUS

MGI Mouse Phenotypes related to Dementia:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.4 APOE APP C9orf72 GBA GRN ITM2B
2 cellular MP:0005384 10.39 APOE APP C9orf72 CHCHD10 GBA GRN
3 growth/size/body region MP:0005378 10.37 APOE APP C9orf72 GBA GRN MAPT
4 hematopoietic system MP:0005397 10.29 APOE APP C9orf72 GBA GRN MAPT
5 immune system MP:0005387 10.28 APOE APP C9orf72 GBA GRN MAPT
6 homeostasis/metabolism MP:0005376 10.27 APOE APP GBA GRN MAPT PRNP
7 mortality/aging MP:0010768 10.21 APOE APP C9orf72 GBA GRN MAPT
8 nervous system MP:0003631 10.19 APOE APP C9orf72 CHMP2B GBA GRN
9 integument MP:0010771 10.06 APOE APP GBA MAPT PRNP PSEN1
10 muscle MP:0005369 9.87 APOE APP MAPT PRNP PSEN1 TARDBP
11 no phenotypic analysis MP:0003012 9.85 APOE APP C9orf72 GRN ITM2B MAPT
12 normal MP:0002873 9.56 APP GBA MAPT PRNP PSEN1 SNCA
13 skeleton MP:0005390 9.32 APOE GBA PRNP PSEN1 SNCA SNCB

Drugs & Therapeutics for Dementia

Drugs for Dementia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 911)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-61-6, 62-31-7 681
2
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 19982-08-2 4054
3
Levodopa Approved Phase 4,Phase 2,Phase 3,Phase 1 59-92-7 6047
4
Citalopram Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 59729-33-8 2771
5
Galantamine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 357-70-0 9651
6
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 106266-06-2 5073
7
Donepezil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 120014-06-4 3152
8
Huperzine A Approved, Experimental Phase 4,Phase 2,Phase 3,Early Phase 1 102518-79-6
9
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 94-09-7, 1994-09-7 2337
10 tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
11
Metformin Approved Phase 4,Phase 3,Phase 2 657-24-9 14219 4091
12
Rivastigmine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 123441-03-2 77991
13
Ketamine Approved, Vet_approved Phase 4,Phase 3 6740-88-1 3821
14
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 1,Not Applicable 2078-54-8 4943
15
Remifentanil Approved Phase 4 132875-61-7 60815
16
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-84-3 187
17
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-28-2 5757
18
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 71-58-9
19
Polyestradiol phosphate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 28014-46-2
20 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 979-32-8
21
Progesterone Approved, Vet_approved Phase 4,Phase 2,Phase 3 57-83-0 5994
22
Nimodipine Approved, Investigational Phase 4,Phase 2,Phase 1 66085-59-4 4497
23
Aspirin Approved, Vet_approved Phase 4,Not Applicable 50-78-2 2244
24
Glucosamine Approved, Investigational Phase 4,Not Applicable 3416-24-8 439213
25
Cilostazol Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 73963-72-1 2754
26
Rasagiline Approved Phase 4,Phase 2 136236-51-6 3052776
27
Probucol Approved, Investigational Phase 4,Phase 1,Phase 2 23288-49-5 4912
28
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 93-14-1 3516
29
leucovorin Approved Phase 4,Phase 3,Phase 2,Not Applicable 58-05-9 6006 143
30
Methylcobalamin Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 13422-55-4
31
Hydroxocobalamin Approved Phase 4,Phase 3,Phase 2,Not Applicable 13422-51-0 11953898 44475014
32
Armodafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 112111-43-0
33
Modafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 68693-11-8 4236
34
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 113-45-1 4158
35
Dextromethorphan Approved Phase 4,Phase 3,Phase 1,Phase 2 125-71-3 5360696 5362449
36
Ibuprofen Approved Phase 4,Phase 3,Phase 1,Early Phase 1 15687-27-1 3672
37
Nicotine Approved Phase 4,Phase 2,Phase 1,Not Applicable 54-11-5 942 89594
38
Lithium carbonate Approved Phase 4,Phase 3,Phase 1,Phase 2 554-13-2
39
Sevoflurane Approved, Vet_approved Phase 4,Not Applicable 28523-86-6 5206
40
Isoflurane Approved, Vet_approved Phase 4,Phase 1,Not Applicable 26675-46-7 3763
41
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 1,Early Phase 1 99-66-1 3121
42
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
43
Acetaminophen Approved Phase 4,Phase 2,Phase 3 103-90-2 1983
44
Hydrocodone Approved, Illicit, Investigational Phase 4 125-29-1 5284569
45
Sertraline Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 79617-96-2 68617
46
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 61869-08-7 43815
47
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 52485-79-7 40400 644073
48
Methamphetamine Approved, Illicit Phase 4,Not Applicable 537-46-2 10836
49
Olanzapine Approved, Investigational Phase 4,Phase 3,Not Applicable 132539-06-1 4585
50 Piracetam Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 7491-74-9

Interventional clinical trials:

(show top 50) (show all 3481)
# Name Status NCT ID Phase Drugs
1 Memantine for Agitation in Dementia Unknown status NCT00371059 Phase 4 Memantine;Placebo
2 Dopaminergic Enhancement of Learning and Memory in Healthy Adults and Patients With Dementia/Mild Cognitive Impairment Unknown status NCT00306124 Phase 4 Levodopa
3 Study of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer’s Disease, Vascular Dementia, and Mixed Vascular and Alzheimer’s Dementia Unknown status NCT00229333 Phase 4 Escitalopram
4 The Relationship Between Risperdal Treatment and Quality of Life in Patients With Alzheimer's Disease and Behavioural and Psychological Symptoms of Dementia (BPSD) Unknown status NCT00626613 Phase 4 Risperdal,reminyl
5 Effect of Cognitive Intervention in Alzheimer's Disease (AD) on Functional Cortical Networks in fMRI Unknown status NCT01329601 Phase 4
6 CALM-AD Unknown status NCT00142324 Phase 4 Donepezil
7 Huperzine-A to Help With Mental Problems and the Inability to Care for Onself in Patients With Schizophrenia Unknown status NCT01012830 Phase 4 Huperzine A
8 Effect of Memantine Oral Pump on Language in Patients With Probable Alzheimer's Disease Unknown status NCT01849042 Phase 4 Ebixa;donepezil
9 Donepezil and Memantine in Moderate to Severe Alzheimer's Disease Unknown status NCT00866060 Phase 4 Memantine;Donepezil;Placebo donepezil;Placebo memantine
10 Insulin Resistance and Mild Cognitive Impairment (IRMCI) Study Unknown status NCT02409238 Phase 4 Metformin
11 Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVD Unknown status NCT02444637 Phase 4 Rivastigmine
12 Transcranial Magnetic Stimulation for Apathy in Mild Cognitive Impairment:Pilot Study Unknown status NCT02190019 Phase 4
13 Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:A Randomized Controlled Trial Unknown status NCT00196703 Phase 4 memantine
14 Cognitive Decline in Non-demented PD Unknown status NCT01340885 Phase 4 Strattera;Exelon
15 Study Effects of Ginkgo Biloba Extract on Endothelial Cell Function and Genetic Effects on the Response to Ginkgo Biloba Extract in Diabetic Patients With Stable Coronary Artery Disease Unknown status NCT01038050 Phase 4 Ginkgo Biloba Extract (GBE)
16 The Role of Ketamine in Preventing Cognitive Dysfunctions in Postoperative Period of Cardiac Surgery Unknown status NCT02782429 Phase 4 Ketamine
17 Diffusion Tensor Weighted MRI in Alzheimer's Disease Modifying Treatment Effects of Galantamine (Reminyl®) Unknown status NCT00523666 Phase 4 Galantamine (Reminyl®);Placebo/Galantamine (Reminyl®)
18 The Effect on the Older's Cognition of Dual-loop Target Controlled Infusion Guided by Narcotrend Index Unknown status NCT03010098 Phase 4
19 Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Spectrum Disorders Unknown status NCT01098383 Phase 4 Acetyl-Choline Esterase Inhibitors and Choline supplements;Indistinguishable placebo tablets, matching both donepezil and choline
20 Multi-centre Clinical Trial on Hormone Replacement Treatment in China Unknown status NCT01698164 Phase 4 estradiol plus MPA;Ximingting Tablet;estradiol plus progesterone
21 Efficacy and Safety Study of Nimodipine to Prevent Mild Cognitive Impairment After Acute Ischemic Strokes Unknown status NCT01220622 Phase 4 Nimodipine;Placebo
22 Efficacy Study of Cilostazol and Aspirin on Cerebral Small Vessel Disease Unknown status NCT01932203 Phase 4 aspirin;cilostazol
23 Evaluation of the Efficacy of Rasagiline in Apathy in Drug-naïve Patients With Parkinson's Disease by a Multi-center Study Unknown status NCT01765257 Phase 4 AZILECT®;Placebo
24 Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging Unknown status NCT02931136 Phase 4 Huperzine A;Placebo
25 A Clinical Trial for an Evaluation of Choline Alfoscerate and Donepezil for Cognitive Improvements of Patients With Cerebrovascular Injury in Alzheimer Patients Unknown status NCT02648906 Phase 4 Choline alfoscerate;Placebo
26 Study of Memantine to Treat Huntington's Disease Unknown status NCT00652457 Phase 4 Memantine
27 PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage Unknown status NCT01013532 Phase 4 Cilostazol;Probucol;Aspirin;placebo of cilostazol;placebo of aspirin
28 Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT) Completed NCT00385684 Phase 4 hydrocodone/APAP w placebo PRN;hydrocodone/APAP;placebo with hydrocodone/APAP PRN
29 Cilostazol Augmentation Study in Dementia Completed NCT01409564 Phase 4 Cilostazol;Placebo
30 Corticolimbic Degeneration and Treatment of Dementia Completed NCT00768261 Phase 4 Memantine (Namenda®);Donepezil (Aricept®)
31 Efficacy and Safety of Donepezil Hydrochloride (Aricept) in Vascular Dementia Completed NCT00165763 Phase 4 donepezil hydrochloride (Aricept)
32 Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia Completed NCT01585272 Phase 4 ENA713
33 Dementia Antipsychotics And Antidepressants Discontinuation Study Completed NCT00594269 Phase 4 Risperidone;Escitalopram;Citalopram;Sertraline;Paroxetine
34 Efficacy of Pain Treatment on Depression in Patients With Dementia Completed NCT02267057 Phase 4 Paracetamol;Buprenorphine;Paracetamol placebo;Buprenorphine placebo
35 Can Oral Vitamin B12 and Folate Supplementation Preserve Cognitive Function of Patients With Early Dementia? Completed NCT00164970 Phase 4
36 The Use of Galantamine (Reminyl ER) in Patients With MIXed Dementia: Effects on Cognition and Quality of Life Completed NCT00814658 Phase 4 Galantamine;Nimodipine;Placebo
37 Effect of Melatonin on Sleep Quality in Patients Dementia Completed NCT03066518 Phase 4 Melatonin 5 mg
38 Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal Dementia Completed NCT00376051 Phase 4 Citalopram
39 Memantine Versus Placebo in Parkinson's Disease Dementia or Dementia With Lewy Bodies Completed NCT00855686 Phase 4 Memantine;Placebo
40 A Post-Marketing Clinical Study of Aricept in Patients With Dementia With Lewy Bodies (DLB) Completed NCT02345213 Phase 4 E2020;Placebo
41 "Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies" Completed NCT01023672 Phase 4 Armodafinil
42 A Study of Donepezil Hydrochloride in Patients With Dementia Associated With Cerebrovascular Disease Completed NCT02660983 Phase 4 Donepezil hydrochloride;Donepezil matching placebo
43 Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia Completed NCT00545974 Phase 4 memantine;Placebo pill
44 Interventional, Randomised, Double-blind, Study to Evaluate the Safety and Tolerability of Once Daily Versus Twice Daily Memantine Treatment in Patients With Dementia of Alzheimer's Type and Mini Mental State Examination (MMSE)Range 5 - 18 Completed NCT02553928 Phase 4 Memantine (once daily);Memantine (twice daily)
45 Study on the Efficacy of Speed-Feedback Therapy for Elderly People With Dementia Completed NCT00450047 Phase 4
46 Methylphenidate for Apathy in Alzheimer's Dementia: A Controlled Study Completed NCT00495820 Phase 4 Methylphenidate
47 Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White Matter Lesions Completed NCT00847860 Phase 4 Cilostazol;Aspirin
48 Discontinuation of Antipsychotics and Antidepressants Among Patients With BPSD Completed NCT00433121 Phase 4 Risperidone;Olanzapine;Haloperidole;Quetiapin;Escitalopram;Citalopram;Sertralin
49 A Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia Completed NCT00947531 Phase 4 Cerebrolysin;0.9% Saline Solution
50 Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP) Completed NCT00043849 Phase 4 Quetiapine

Search NIH Clinical Center for Dementia

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: dementia

Genetic Tests for Dementia

Genetic tests related to Dementia:

# Genetic test Affiliating Genes
1 Dementia 29

Anatomical Context for Dementia

MalaCards organs/tissues related to Dementia:

41
Brain, Testes, Heart, Cortex, Bone, Kidney, Temporal Lobe

Publications for Dementia

Articles related to Dementia:

(show top 50) (show all 8427)
# Title Authors Year
1
Anxiety and risk of dementia: Systematic review and meta-analysis of prospective cohort studies. ( 30502746 )
2019
2
Setting matters: Associations of nurses' attitudes towards people with dementia. ( 30534405 )
2019
3
Examining the Perceived Effects of an Adult Day Program for Individuals With Dementia and Their Caregivers: A Qualitative Investigation. ( 30499847 )
2019
4
Process evaluation of a social support platform 'Inlife' for caregivers of people with dementia. ( 30510911 )
2019
5
Beta amyloid deposition maps onto hippocampal and subiculum atrophy in dementia with Lewy bodies. ( 30339962 )
2019
6
ATXN2 intermediate repeat expansions influence the clinical phenotype in frontotemporal dementia. ( 30342763 )
2019
7
Striking phenotypic variation in a family with the P506S UBQLN2 mutation including amyotrophic lateral sclerosis, spastic paraplegia, and frontotemporal dementia. ( 30348461 )
2019
8
APOE ɛ4, rs405509, and rs440446 promoter and intron-1 polymorphisms and dementia risk in a cohort of elderly Finns-Helsinki Birth Cohort Study. ( 30293724 )
2019
9
Effect of rivastigmine on plasma butyrylcholine esterase activity and plasma ghrelin levels in patients with dementia in Alzheimer's disease. ( 29441654 )
2018
10
Enhanced Positive Emotional Reactivity Undermines Empathy in Behavioral Variant Frontotemporal Dementia. ( 29915557 )
2018
11
Executive and social-cognitive determinants of environmental dependency syndrome in behavioral frontotemporal dementia. ( 29809029 )
2018
12
Anosognosia predicts default mode network hypometabolism and clinical progression to dementia. ( 29444971 )
2018
13
A new device-aided cognitive function test, User eXperience-Trail Making Test (UX-TMT), sensitively detects neuropsychological performance in patients with dementia and Parkinson's disease. ( 29976167 )
2018
14
Meaning of psychiatric symptoms in frontotemporal dementia. ( 29439161 )
2018
15
Dementia management: a brief overview for primary care clinicians. ( 29974121 )
2018
16
Strategic value-directed learning and memory in Alzheimer's disease and behavioural-variant frontotemporal dementia. ( 29431279 )
2018
17
Visual texture agnosia in dementia with Lewy bodies and Alzheimer's disease. ( 29673784 )
2018
18
Molecular Genetics of Frontotemporal Dementia Elucidated by <i>Drosophila</i> Models-Defects in Endosomala8>Lysosomal Pathway. ( 29890743 )
2018
19
Vascular dementia: clinicopathologic and genetic considerations. ( 29380913 )
2018
20
Predicting outcome of Morris water maze test in vascular dementia mouse model with deep learning. ( 29415035 )
2018
21
Correction: Immune-related genetic enrichment in frontotemporal dementia: An analysis of genome-wide association studies. ( 29377952 )
2018
22
Posterior Associative and Cingulate Cortex Involvement of Brain Single-Photon Emission Computed Tomography (SPECT) Imaging in Semantic Dementia with Probable Alzheimer Disease Pathology: A Case Report. ( 29429985 )
2018
23
Chinese Herbal Medicine for Vascular Dementia: A Systematic Review and Meta-Analysis of High-Quality Randomized Controlled Trials. ( 29439346 )
2018
24
Genomea89wide DNA methylation profiling in a rat model with vascular dementia. ( 29749552 )
2018
25
Differential diagnosis of unexplained falls in dementia: Results of &amp;quot;Syncope &amp;amp; Dementia&amp;quot; registry. ( 29398249 )
2018
26
Diagnosing pre-clinical dementia: the NZ Genetic Frontotemporal Dementia Study (FTDGeNZ). ( 29879731 )
2018
27
Trichotillomania Ranging from &amp;quot;Ritual to Illness&amp;quot; and as a Rare Clinical Manifestation of Frontotemporal Dementia: Review of Literature and Case Report. ( 29769783 )
2018
28
Betulinic acid, a natural PDE inhibitor restores hippocampal cAMP/cGMP and BDNF, improve cerebral blood flow and recover memory deficits in permanent BCCAO induced vascular dementia in rats. ( 29778746 )
2018
29
Neurovascular dysfunction in dementia - human cellular models and molecular mechanisms. ( 29444850 )
2018
30
Plasma amyloid-I^ levels, cerebral atrophy and risk of dementia: a population-based study. ( 29960604 )
2018
31
Affective Empathy in Behavioral Variant Frontotemporal Dementia: A Meta-Analysis. ( 29946291 )
2018
32
Stroke Risk and Vascular Dementia in South Asians. ( 29974259 )
2018
33
Frontotemporal dementia with Parkinsonism linked to chromosome-17 mutations enhance tau oligomer formation. ( 29852407 )
2018
34
Potential of carnosine, a histamine precursor in rat model of bilateral common carotid artery occlusion-induced vascular dementia. ( 29676814 )
2018
35
Special Issue on mild behavioral impairment and non-cognitive prodromes to dementia. ( 29448971 )
2018
36
Cathepsin D Polymorphism C224T in Childhood-Onset Neurodegenerative Disorders: No Impact for Childhood Dementia. ( 29441216 )
2018
37
Polypharmacy in people with dementia: Associations with adverse health outcomes. ( 29452289 )
2018
38
Relationships Between Cognitive Complaints and Quality of Life in Older Adults With Mild Cognitive Impairment, Mild Alzheimer Disease Dementia, and Normal Cognition. ( 29944474 )
2018
39
Sleep Apnea Is a Risk Factor for Stroke and Vascular Dementia. ( 29938308 )
2018
40
The involvement of neuroinflammation and necroptosis in the hippocampus during vascular dementia. ( 29759140 )
2018
41
Lipid Metabolism and Survival Across the Frontotemporal Dementia-Amyotrophic Lateral Sclerosis Spectrum: Relationships to Eating Behavior and Cognition. ( 29254092 )
2018
42
Tau-negative amnestic dementia masquerading as Alzheimer disease dementia. ( 29438037 )
2018
43
Plasma tau is increased in frontotemporal dementia. ( 29440230 )
2018
44
Positive age beliefs protect against dementia even among elders with high-risk gene. ( 29414991 )
2018
45
Combined Socio-Behavioral Evaluation Improves the Differential Diagnosis Between the Behavioral Variant of Frontotemporal Dementia and Alzheimer's Disease: In Search of Neuropsychological Markers. ( 29254091 )
2018
46
When Post-Traumatic Stress Disorder and Charles Bonnet Syndrome Become Lewy Body Dementia. ( 29778582 )
2018
47
Why do herpes simplex encephalitis and semantic dementia show a different pattern of semantic impairment in spite of their main common involvement within the anterior temporal lobes? ( 29573378 )
2018
48
Reply: Cerebrospinal Fluid, Hyposmia and Dementia in Alzheimer Disease: Insights from Dynamic PET and a Hypothesis. ( 29439014 )
2018
49
Regional structural hypo- and hyperconnectivity of frontal-striatal and frontal-thalamic pathways in behavioral variant frontotemporal dementia. ( 29923666 )
2018
50
Distinct Interplay Between Atrophy and Hypometabolism in Alzheimer's Versus Semantic Dementia. ( 29668866 )
2018